DAT-2645 tablet

DRUG2 trials

Sponsors

Danatlas Pharmaceuticals Co., Ltd

Conditions

Advanced CancerAdvanced or Metastatic Ovarian CancerBRCA MutationBreast CancerColorectal CancerEndometrial CancerGastric CancerHRD Cancer

Phase 1

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

Not yet recruitingNCT06614751

Danatlas Pharmaceuticals Co., LtdAdvanced Cancer, BRCA Mutation, Breast Cancer +8

Start: 2024-11-01End: 2027-06-01Target: 112Updated: 2024-09-27

Phase 2

A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer

Not yet recruitingNCT07652073

Danatlas Pharmaceuticals Co., LtdAdvanced or Metastatic Ovarian Cancer

Start: 2026-06-15End: 2028-03-30Target: 30Updated: 2026-06-25